TaiMed Biologics, Inc., a biotechnology company, engages in the discovery, development, and delivery of medicines primarily for HIV/AIDS in Taiwan. Its products pipeline include TMB-355, a phase IIb viral-entry inhibitor that blocks humanized mAb to treat HIV/AIDS; TMB-358, which is a preclinical stage development medicine that retains the anti-HIV activity of the parent molecule; and Tamiphosphor, a small molecule inhibitor of influenza virus neuraminidase. The company was founded in 2007 and is based in Taipei, Taiwan.